Invest In Biomed is a unique Eurobiomed program that helps innovative healthcare companies consolidate their fund-raising approach and tools, and introduces them to specialized investors in the sector. To mark the launch of the 10e edition of this program, we give the floor to entrepreneurs who have benefited from it.
Arnaud Debains and Sandrine Isz are respectively Chief Financial Officer and Chief Science Officer of BOYDSense, a young company developing innovative respiratory analysis technology, enabling patients to easily track their state of health and monitor their chronic pathologies, notably diabetes. Winner of Eurobiomed's Invest In Biomed program in 2023, BOYDSense raised a round of financing in April 2024.
What prompted you to join the Invest In Biomed program?
Arnaud Debains: After developing our technology, we realized that it was complicated to attract the attention of investors without first working on our communications.
It's a delicate balancing act: you have to be able to share enough information to arouse interest, while at the same time preserving our industrial secrets. The program helped us to find this balance, to improve the way we tell our story, and to come out of our reserve, because we had some interesting achievements to showcase.
How did the program help you structure your pitch deck?
Sandrine Isz: Working on our pitch deck was particularly rewarding. On Eurobiomed's advice, we added a fundamental slide presenting the technical and scientific aspects of our innovation.
Although reluctant at first for fear of revealing too much, this slide has become a key element that we still use today in all our presentations. It reassures investors that our project is technologically sound.
What did you gain from pitching to investors?
Arnaud Debains: These sessions were useful, even if the investors present weren't directly involved in our April 2024 fund-raising, carried out with investors specialized in diabetes and backed by a Horizon 2020 grant.
Through the Invest In Biomed pitch sessions, we have established lasting contacts with a number of investors who continue to follow our progress. They regularly ask us for news, and we maintain these relationships, which may prove invaluable in the future. It's a network built over the long term.
SIMILAR ARTICLES :
Amaury Ciurana (REEV): "The Invest In Biomed program offered us a privileged framework for building relationships of trust with our investors".
Philippe Andres (Tarian Pharma): "Invest In Biomed's support enabled us to adapt our language to that of investors".
